Home
Live Updates
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones : vimarsana.com
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product sales...
Related Keywords
,
Neurocrine Biosciences ,
Kevin Gorman ,
Neurocrine Biosciences Inc ,
Sosei Group Corporation ,
Linkedin ,
Mitsubishi Tanabe Pharma Corporation ,
Takeda Pharmaceutical Company ,
Nasdaq ,
Xenon Pharmaceuticals ,
Idorsia Pharmaceuticals ,
Chief Executive Officer ,
Healthcare Conference ,
Fourth Quarter ,
Net Product Sales ,
Future Milestones ,
Supplemental New Drug Application ,
Second Half ,
Registrational Study ,
Top Line Registrational Data ,
Line Registrational Data ,
Selectivet Type ,
Line Phase ,
Pediatric Epilepsy ,
Adrenal Hyperplasia ,
Onset Seizure ,
Vesicular Monoamine Transporter ,
Calcium Channel ,
Epileptic Encephalopathy ,
Continuous Spike ,
Wave During Sleep ,
Corticotropin Releasing Factor Type ,
Isoxazole Propionic Acid ,
Protein Coupled Receptor ,
Sodium Channel ,
Bioscience Partners ,
East Asia ,
Takeda Pharmaceutical Company Limited ,
Tardive Dyskinesia ,
Nc ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Biotechnology ,
vimarsana.com © 2020. All Rights Reserved.